To the Editor: Type B insulin resistance is an uncommon syndrome characterised by abnormal glucose homeostasis (hypo- and/or hyperglycaemia), the presence of insulin receptor (IRec) autoantibodies, and intact IRec structure. It occurs mostly in African Americans, often with coexisting autoimmune disease.1
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- Hunter Area Pathology Service, Newcastle University, Newcastle, NSW.
Correspondence: huy.tran@hnehealth.nsw.gov.au
- 1. Arioglu E, Andewelt A, Diabo C, et al. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002; 81: 87-100.
- 2. Flier JS, Kahn CR, Roth J. Receptors, antireceptor antibodies and mechanisms of insulin resistance. N Engl J Med 1979; 300: 413-419.
- 3. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976; 294: 739-745.
- 4. Eriksson JW, Bremell T, Eliasson B, et al. Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Case report. Diabetes Care 1998; 21: 1217-1220.
- 5. Coll AP, Thomas S, Mufti GJ. Rituximab therapy for the type B syndrome of severe insulin resistance. N Engl J Med 2004; 350: 310-311.
Online responses are no longer available. Please refer to our instructions for authors page for more information.